Product news from the 02/13/07 news brief

Share this article:
Pfizer said the FDA has approved new labeling of Sutent (sunitinib malate) which includes first-line treatment of advanced renal cell carcinoma, a type of advanced kidney cancer, based on results of a large Phase III trial, which showed prolonged progression-free survival. Mylan Laboratories and Barr Pharmaceuticals became the second and third drugmakers to receive FDA approval to sell generic versions of Pfizer’s blockbuster antidepressant Zoloft (sertraline). Both companies said they would begin shipping the product immediately. Pfizer lost patent protection on Zoloft last August. Branded Zoloft sales fell 79% in Pfizer’s fourth quarter to $166 million, compared with $808 million in the same period a year earlier. Teva Pharmaceutical was able to sell the only generic version during the first six months after expiration of Zoloft’s patent, under a federally enforced exclusivity period.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.